{
  "id": 16528274,
  "title": "#ESMO26: Akeso details ivonescimab's biliary cancer success, drawing Keytruda comparisons",
  "url": "https://urgent.news/2026/10/25/esmo26-akeso-details-ivonescimabs-biliary-cancer-success-drawing",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-25T21:43:13.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/esmo26-akeso-details-ivonescimabs-biliary-cancer-success-drawing-keytruda-comparisons/"
  },
  "original_language": "en",
  "account": null,
  "summary": "MADRID — Akeso on Sunday spelled out by how much its Summit Therapeutics-partnered PD-1xVEGF bispecific improved survival in a late-stage, China-only biliary tract cancer study, in one of its early moves to find success beyond ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "AstraZeneca stomach cancer drug doubles survival in late-stage trial",
        "url": "https://urgent.news/2026/10/25/astrazeneca-stomach-cancer-drug-doubles-survival-in-late-stage-trial",
        "published": "2026-10-25T16:17:03.000Z"
      },
      {
        "outlet": "STAT News",
        "title": "STAT+: At ESMO, AstraZeneca’s cancer pursuits get a showcase",
        "url": "https://urgent.news/2026/10/25/stat-at-esmo-astrazenecas-cancer-pursuits-get-a-showcase",
        "published": "2026-10-25T16:58:45.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}